Pasar al contenido principal

TECNOLOGIAS AVANZADAS PARA LA INSERCION PRECISA Y EFICIENTE DE GENES

PID2020-118597RB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2020
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSITAT POMPEU FABRA CCT

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

CRISPR-Analytics (CRISPR-A): A platform for precise analytics and simulations for gene editing

  • Sanvicente-García, Marta
  • García Valiente, Albert
  • Jouide, Socayna
  • Jaraba-Wallace, Jessica
  • Bautista, Eric
  • Escobosa Olmo, Marc
  • Sánchez-Mejías, Avencia
  • Güell Cargol, Marc, 1982-
Gene editing characterization with currently available tools does not always give precise relative proportions among the different types of gene edits present in an edited bulk of cells. We have developed CRISPR-Analytics, CRISPR-A, which is a comprehensive and versatile genome editing web application tool and a nextflow pipeline to give support to gene editing experimental design and analysis. CRISPR-A provides a robust gene editing analysis pipeline composed of data analysis tools and simulation. It achieves higher accuracy than current tools and expands the functionality. The analysis includes mock-based noise correction, spike-in calibrated amplification bias reduction, and advanced interactive graphics. This expanded robustness makes this tool ideal for analyzing highly sensitive cases such as clinical samples or experiments with low editing efficiencies. It also provides an assessment of experimental design through the simulation of gene editing results. Therefore, CRISPR-A is ideal to support multiple kinds of experiments such as double-stranded DNA break-based engineering, base editing (BE), primer editing (PE), and homology-directed repair (HDR), without the need of specifying the used experimental approach., This work was supported by the European Commission (European Union Horizon 2020 grant 825825 to MG), Ramón y Cajal program (grant RYC-2015-17734 to MG), Fundación Ramón Areces (grant “Advanced gene editing technologies to restore LAMA2 on merosin-deficient congenital muscular dystrophy type 1A” to MG) and Ministerio de Ciencia e Innovación de España (Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 «Advanced methodologies for precise and efficient gene delivery» grant PID2020-118597RB-I00 to MG). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Discovery and protein language model-guided design of hyperactive transposases

  • Ivančić, Dimitrije
  • Agudelo, Alejandro
  • Lindstrom-Vautrin, Jonathan
  • Jaraba-Wallace, Jessica
  • Gallo, María, 1989-
  • Das, Ravi
  • Ragel, Alejandro
  • Herrero-Vicente, Jorge
  • Higueras, Irene
  • Billeci, Federico
  • Sanvicente-García, Marta
  • Petazzi, Paolo
  • Ferruz Capapey, Noelia, 1988-
  • Sánchez-Mejías, Avencia
  • Güell Cargol, Marc, 1982-
Data de publicació electrònica: 02-10-2025, The diversity and biochemical potential of the PiggyBac transposase gene insertion system remains largely unexplored. Using a eukaryotic transposon mining pipeline, we expand the explored diversity by two orders of magnitude and experimentally validate a subset of highly divergent PiggyBac sequences. Fine-tuning a protein language model to further expand PiggyBac sequence space discovers transposases with improved activity and that are compatible with T cell engineering and Cas9-directed transposase-assisted integration., We thank C. Feschotte for feedback on the transposon bioprospecting pipeline, G. M. Church for advice on approaches for machine learning, AI and directed evolution and M. Artigues for her help in designing the initial filtering process for the Progen2 generated sequences. Integra Therapeutics received funding from NEOTEC (CDTI, SNEO-20222363). Universitat Pompeu Fabra received funding from UPGRADE (European Union Horizon 2020, grant agreement no. 825825) and Ministerio de Economia, Industria y Competitividad de España (Plan Estatal 2013-2016 (grant agreement no. PID2020-118597RB-I00).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Discovery and protein language model-guided design of hyperactive transposases

  • Ivančić, Dimitrije
  • Agudelo, Alejandro
  • Lindstrom-Vautrin, Jonathan
  • Jaraba-Wallace, Jessica
  • Gallo, María, 1989-
  • Das, Ravi
  • Ragel, Alejandro
  • Herrero-Vicente, Jorge
  • Higueras, Irene
  • Billeci, Federico
  • Sanvicente-García, Marta
  • Petazzi, Paolo
  • Ferruz Capapey, Noelia, 1988-
  • Sánchez-Mejías, Avencia
  • Güell Cargol, Marc, 1982-
Data de publicació electrònica: 02-10-2025, The diversity and biochemical potential of the PiggyBac transposase gene insertion system remains largely unexplored. Using a eukaryotic transposon mining pipeline, we expand the explored diversity by two orders of magnitude and experimentally validate a subset of highly divergent PiggyBac sequences. Fine-tuning a protein language model to further expand PiggyBac sequence space discovers transposases with improved activity and that are compatible with T cell engineering and Cas9-directed transposase-assisted integration., We thank C. Feschotte for feedback on the transposon bioprospecting pipeline, G. M. Church for advice on approaches for machine learning, AI and directed evolution and M. Artigues for her help in designing the initial filtering process for the Progen2 generated sequences. Integra Therapeutics received funding from NEOTEC (CDTI, SNEO-20222363). Universitat Pompeu Fabra received funding from UPGRADE (European Union Horizon 2020, grant agreement no. 825825) and Ministerio de Economia, Industria y Competitividad de España (Plan Estatal 2013-2016 (grant agreement no. PID2020-118597RB-I00).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

CRISPR-Analytics (CRISPR-A): A platform for precise analytics and simulations for gene editing

  • Sanvicente-García, Marta
  • García Valiente, Albert
  • Jouide, Socayna
  • Jaraba-Wallace, Jessica
  • Bautista, Eric
  • Escobosa Olmo, Marc
  • Sánchez-Mejías, Avencia
  • Güell Cargol, Marc, 1982-
Gene editing characterization with currently available tools does not always give precise relative proportions among the different types of gene edits present in an edited bulk of cells. We have developed CRISPR-Analytics, CRISPR-A, which is a comprehensive and versatile genome editing web application tool and a nextflow pipeline to give support to gene editing experimental design and analysis. CRISPR-A provides a robust gene editing analysis pipeline composed of data analysis tools and simulation. It achieves higher accuracy than current tools and expands the functionality. The analysis includes mock-based noise correction, spike-in calibrated amplification bias reduction, and advanced interactive graphics. This expanded robustness makes this tool ideal for analyzing highly sensitive cases such as clinical samples or experiments with low editing efficiencies. It also provides an assessment of experimental design through the simulation of gene editing results. Therefore, CRISPR-A is ideal to support multiple kinds of experiments such as double-stranded DNA break-based engineering, base editing (BE), primer editing (PE), and homology-directed repair (HDR), without the need of specifying the used experimental approach., This work was supported by the European Commission (European Union Horizon 2020 grant 825825 to MG), Ramón y Cajal program (grant RYC-2015-17734 to MG), Fundación Ramón Areces (grant “Advanced gene editing technologies to restore LAMA2 on merosin-deficient congenital muscular dystrophy type 1A” to MG) and Ministerio de Ciencia e Innovación de España (Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 «Advanced methodologies for precise and efficient gene delivery» grant PID2020-118597RB-I00 to MG). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.